Patents by Inventor Sheng-Bin Peng

Sheng-Bin Peng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9334267
    Abstract: This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: May 10, 2016
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Patent number: 9187474
    Abstract: This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: November 17, 2015
    Assignees: Deciphera Pharmaceuticals, LLC, Eli Lilly and Company
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, Timothy Malcolm Caldwell, William C. Patt, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Publication number: 20150119392
    Abstract: This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers.
    Type: Application
    Filed: March 5, 2013
    Publication date: April 30, 2015
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Publication number: 20150105367
    Abstract: This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.
    Type: Application
    Filed: March 5, 2013
    Publication date: April 16, 2015
    Inventors: Daniel L. Flynn, Michael D, Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, Timothy Malcolm Caldwell, William C. Patt, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Patent number: 8003102
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: August 23, 2011
    Assignee: Eli Lilly and Company
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • Publication number: 20110086027
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Application
    Filed: December 17, 2010
    Publication date: April 14, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • Patent number: 7892546
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: February 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • Publication number: 20100285005
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Application
    Filed: May 7, 2009
    Publication date: November 11, 2010
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • Publication number: 20100130409
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Application
    Filed: January 25, 2010
    Publication date: May 27, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
  • Patent number: 7691813
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: April 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
  • Publication number: 20080300177
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Application
    Filed: May 20, 2008
    Publication date: December 4, 2008
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
  • Patent number: 6951840
    Abstract: Provided are novel lipoglycopeptides exhibiting bacterial signal peptidase inhibitory activity. Also provided are actinomycete strains that produce these lipoglycopeptides, methods of producing such lipoglycopeptides by culturing these strains, pharmaceutical compositions comprising these lipoglycopeptides, and methods of treating bacterial infections comprising contacting bacteria susceptible to treatment with the present bacterial signal peptidase inhibitor lipoglycopeptides. These lipoglycopeptides are useful in human and veterinary medicine.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: October 4, 2005
    Assignee: Eli Lilly and Company
    Inventors: Matthew David Belvo, Adam Joseph Kreuzman, Palaniappan Kulanthaivel, Sheng-Bin Peng, Tim Allen Smitka
  • Publication number: 20030130172
    Abstract: Provided are novel lipoglycopeptides exhibiting bacterial signal peptidase inhibitory activity. Also provided are actinomycete strains that produce these lipoglycopeptides, methods of producing such lipoglycopeptides by culturing these strains, pharmaceutical compositions comprising these lipoglycopeptides, and methods of treating bacterial infections comprising contacting bacteria susceptible to treatment with the present bacterial signal peptidase inhibitor lipoglycopeptides. These lipoglycopeptides are useful in human and veterinary medicine.
    Type: Application
    Filed: August 14, 2002
    Publication date: July 10, 2003
    Inventors: Matthew David Belvo, Adam Joseph Kreuzman, Palaniappan Kulanthaivel, Sheng-Bin Peng, Tim Allen Smitka
  • Patent number: RE42274
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: April 5, 2011
    Assignee: Eli Lilly and Company
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan